sur Cheplapharm Arzneimittel GmbH (isin : DE000CHP2222)
Sandra Schröder Joins CHEPLAPHARM as VP Scientific
On June 1, 2025, Sandra Schröder became the Vice President Scientific at CHEPLAPHARM, a global pharmaceutical company based in Greifswald. This newly created role endows her with the responsibility for scientific oversight across the organization, including Quality, Regulatory Affairs, Pharmacovigilance, and Medical Affairs. Schröder transitions from F. Hoffmann-La Roche AG in Basel, where she amassed over 25 years of management experience.
Sandra Schröder's primary goal as VP Scientific is to maintain product quality and regulatory compliance in all markets. Her duties extend to integrating new products into CHEPLAPHARM's systems. Reporting directly to Dr. Bianca Juha, Chief Scientific Officer, Schröder brings considerable international expertise to her position.
Dr. Bianca Juha emphasized the importance of the VP Scientific role, expressing confidence in Schröder's capability given her extensive background in quality management and regulatory affairs.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Cheplapharm Arzneimittel GmbH